Andere Sprachen Elevation Oncology, Inc.

Aktien

A3CS7V

US28623U1016

ELEV

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.05.2024			% 5 Tage	% 1. Jan.
4 ^USD	+12,68 %		+3,09 %	+644,88 %

05.04.	Elevation Oncology, Inc. kündigt Änderungen im Management an	CI
27.03.	Merrimack erhält $225 Millionen Meilensteinzahlung und setzt Treffen für Auflösungsplan an	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Elevation Oncology, Inc. Announces Management Changes	05.04.
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	27.03.
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements	07.03.
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06.03.
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06.03.
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors	04.03.
Elevation Oncology to Participate in Upcoming Investor Conferences	29.02.
Kaskela Law LLC Announces Shareholder Investigation of Elevation Oncology (ELEV) and Encourages Investors to Contact the Firm	29.02.
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment	22.02.
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan	22.02.
Merrimack Reports Ipsen Announcement of Approval by The US FDA of Onivyde Plus 5 Fluorouracil/Leucovorin and Oxaliplatin as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma	14.02.
Elevation Oncology Announces Appointment of Darcy Mootz, Ph.D., to its Board of Directors	23.01.
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee	22.01.
Latest Buzz on The Street: Noteworthy Developments at DYAI, ELEV, ATRA, ESPR, KAVL	17.01.
Elevation Oncology Says It Has Funds to Continue Operations Into H2 2025	05.01.
Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021	05.01.
Elevation Oncology to Present at the Piper Sandler 35th Annual Healthcare Conference	23.11.
Elevation Oncology Reports Third Quarter 2023 Financial Results and Highlights Recent Business Achievements	03.11.
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02.11.
Certain Restricted Stock Units of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Elevation Oncology, Inc.

Aktien

A3CS7V

US28623U1016

ELEV

Andere Sprachen

Filter